MedTrace Logo

Linagliptin in Post-renal Transplantation

NCT03970668 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2019-06-04

No results posted yet for this study

Summary

Post-renal transplanted patients frequently present hyperglycemia immediately after the procedure.

This was a retrospective comparative study performed in post-renal transplanted patients in a single high speciality center with the goal of compare the effect of linagliptin + insulin in post-renal transplanted patients with hyperglycemia Interventions were linagliptin 5mg daily plus insulin vs insulin alone during 5 days after renal transplantation with hyperglycemia, and the main outcome were glucose levels, insulin dose and severity of hypoglycemia

Conditions

  • Transplanted Kidney Complication

Interventions

DRUG

Linagliptin 5 mg Oral Tablet

Patients received linagliptin 5mg once daily orally plus a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)

DRUG

Insulin

Patients received a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)

Sponsors & Collaborators

  • Hospital Regional de Alta Especialidad del Bajio

    collaborator OTHER

  • Universidad de Guanajuato

    lead OTHER

Principal Investigators

  • Rodolfo Guardado, MD · Hospital Regional de Alta Especialidad del Bajio

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2018-12-31
Completion
2019-04-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03970668 on ClinicalTrials.gov